我要投票 康圣环球在精准医疗行业中的票数:598
· 外 推 电 报 ·
2025-08-20 21:41:44 星期三

【康圣环球是哪个国家的品牌?】

康圣环球是什么牌子?「康圣环球」是康圣环球(北京)医学技术有限公司旗下著名品牌。该品牌发源于北京/海淀区,由创始人黄士昂在2007-11-20期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力康圣环球品牌出海!将品牌入驻外推网,定制康圣环球品牌推广信息,可以显著提高康圣环球产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

康圣环球医学特检集团(以下简称“康圣环球”)是中国首家和最大高端医学专科特检服务检验集团。康圣环球致力于引领中国专科特检技术和服务的进步,以促进中国专科诊疗和个性化医学的发展和提高。本着病人利益至上、医生需求第一的宗旨,康圣环球遵循国际规范、标准和行业指南,引进和研发世界上最先进的技术和专科特检方法,面向中国大型三级医院、专科医院和综合性医院提供全面、先进和准确的专科特检服务。集团创业和管理团队核心成员均在美国学术和产业界工作十年以上,视野广阔,经验丰富。集团得到了世界上最著名和最大的创投基金凯鹏华盈(KPCB)、晨兴创投、中经合、贝雅等几千万美元的资本支持。并在2011年6月27日,美国梅奥医学中心(MayoClinic)宣布与中国康圣环球医学特检集团正式签署一项长达数年的战略合作协议,梅奥向康圣环球注资,通过其医学检验与病理学部及其旗下的梅奥医学实验室,为康圣环球提供近3000项专业检测技术及实验室质量管理,国际认证标准、信息咨询、标准操作程序(SOPs)和方法学等相关技术,协助康圣环球加速发展其在中国的高品质特检服务,促进中国医学诊断和治疗水平的提高。

康圣环球在北京、上海、武汉已建和在建三万八千平方米具有国际先进水平的、具有国家资质的临床检验、科研合作和应用开发中心,拥有高分辨流式细胞仪、多色流式细胞分选与细胞培养、多色荧光适时幼态细胞扫描成像仪、第二代基因组学测序、基因芯片、全自动DNA/RNA提取、COBAS高灵敏度病毒载量系统、高精度质谱、质谱芯片、高压液相/气相层析、分子细胞、遗传与全自动核型扫描、变性高效色谱分析、分子病理、数字病理、液态芯片、单分子数字免疫、免疫组化、蛋白指纹图谱、激光共聚焦显微镜、电子显微镜等数十个技术平台和专业实验室,向全国三十一个省直辖市,六百多个城市的三千多家医院,尤其是千余家大型三级医院提供三千多项血液、肿瘤、遗传、心脑血管、感染性疾病、自身免疫性疾病等领域和内、外、妇、儿等专科的高精尖诊断检测,并通过与全球顶尖医疗科技机构和大型制药公司合作,向全国广大临床医师提供医学科研、药物试验和转化医学研究服务。


英文翻译:Kangsheng global medical special examination group (hereinafter referred to as "Kangsheng global") is the first and largest high-end medical special examination service inspection group in China. Kangsheng global is committed to leading the progress of special examination technology and services in China, so as to promote the development and improvement of specialized diagnosis and treatment and personalized medicine in China. In line with the tenet of putting patients' interests first and doctors' needs first, Kangsheng universal follows international norms, standards and industry guidelines, introduces and develops the most advanced technology and special examination methods in the world, and provides comprehensive, advanced and accurate special examination services for large-scale tertiary hospitals, specialized hospitals and general hospitals in China. The core members of the group's entrepreneurship and management team have worked in the academic and industrial circles of the United States for more than ten years, with broad vision and rich experience. The group has received capital support of tens of millions of US dollars from KPCB, Chenxing venture capital, China economic cooperation and paya, the world's most famous and largest venture capital fund. And on June 27, 2011, Mayoclinic of the United States announced that it has signed a strategic cooperation agreement with China global medical special inspection group for several years. Mayo has invested in global health. Through its Department of medical testing and pathology and its Mayo Medical Laboratory, it has provided global health with nearly 3000 professional testing technologies and laboratory quality management, international certification standards and information Consulting, SOPs, methodology and other related technologies will help Corson global to accelerate the development of its high-quality special examination services in China and promote the improvement of medical diagnosis and treatment level in China. Kangsheng global has established and is in the process of building 38000 square meters of clinical testing, scientific research cooperation and application development center with international advanced level and national qualification in Beijing, Shanghai and Wuhan. It has high-resolution flow cytometry, multi-color flow cell sorting and cell culture, multi-color fluorescence real-time young cell scanning imager, second-generation genomics sequencing, gene chip, and full-scale fluorescence Automatic DNA / RNA extraction, Cobas high-sensitivity viral load system, high-precision mass spectrometry, mass spectrometry chip, high-pressure liquid / gas chromatography, molecular cell, genetic and full-automatic nuclear scanning, denaturing high-performance chromatography, molecular pathology, digital pathology, liquid chip, single molecule digital immune, immunohistochemistry, protein fingerprint, laser confocal microscope, electron microscope, etc Ten technical platforms and professional laboratories provide more than 3000 hospitals in 31 provinces, municipalities directly under the central government and more than 600 cities in China, especially more than 1000 large tertiary hospitals, with more than 3000 high-end diagnostic tests in the fields of blood, tumor, genetics, cardio cerebrovascular, infectious diseases, autoimmune diseases, and in the fields of internal, external, women, children and other specialties, and have passed the world's top doctors Medical science and technology institutions and large pharmaceutical companies cooperate to provide medical research, drug testing and translational medical research services to clinicians across the country.

本文链接: https://www.waitui.com/brand/b8bc6d5cc.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

江波龙:员工持股平台拟合计减持公司不超1.31%股份

36氪获悉,江波龙公告,龙熹一号、龙熹二号、龙熹三号、龙舰管理、龙熹五号(统称“员工持股平台”)合计持有公司16.53%股份,计划在2025年9月11日至12月10日期间通过集中竞价交易方式和大宗交易方式合计减持公司股份不超过548万股(不超过公司总股本的1.31%)。

2小时前

云南锗业:公司及鑫耀公司目前并无6英寸磷化铟晶片规模化量产的具体计划

36氪获悉,云南锗业发布股票交易异常波动公告,公司了解到,近期有国内研发机构发布了其在6英寸磷化铟外延生长工艺领域实现了技术突破相关事宜。就控股子公司鑫耀公司而言,在2-4英寸规格的磷化铟晶片量产后,为应对未来的市场需求,对更大尺寸的产品开展了研究开发,但从研发到规模化生产尚存在较大不确定性。公司及鑫耀公司目前并无6英寸磷化铟晶片规模化量产的具体计划,下一步在市场与需求风险、技术风险等可控的前提下,公司方会考虑相关计划,如有相关计划,公司会按规定进行公开披露。

2小时前

胜宏科技:向香港联交所递交H股发行并上市申请并刊发申请资料

36氪获悉,胜宏科技公告,公司已于2025年8月20日向香港联交所递交了发行境外上市股份(H股)并在香港联交所主板挂牌上市的申请,并于同日在香港联交所网站刊登了本次发行的申请资料。该申请资料为草拟版本,其所载资料可能会适时作出更新及修订。公司本次发行尚需取得相关政府机关、监管机构、证券交易所的批准、核准或备案。

2小时前

永辉超市:上半年净亏损2.41亿元

36氪获悉,永辉超市公告,公司上半年实现营业总收入299.48亿元,同比下降20.73%;净亏损2.41亿元,上年同期盈利2.75亿元。

2小时前

摩根大通与三菱日联接近达成220亿美元的得州数据中心融资协议

英国《金融时报》周三报道,摩根大通和日本三菱日联金融集团正就为得克萨斯州一个数据中心承销220亿美元贷款展开谈判。报道称,该规划中的园区将由Vantage Data Centers所有,这是一家由银湖资本和资产管理公司DigitalBridge 控股的数字基础设施企业。报道还指出,银湖资本和DigitalBridge将合计承诺30亿美元股权,助力该数据中心园区的建设。(新浪财经)

2小时前

本页详细列出关于康圣环球的品牌信息,含品牌所属公司介绍,康圣环球所处行业的品牌地位及优势。
咨询